Abstracts

GREATER WEIGHT GAIN AFTER SWITCH TO InSTI-BASED REGIMEN FROM NNRTI VS PI REGIMENS

Recent reports describe greater weight gain among antiretroviral therapy (ART)-naïve persons with HIV (PWH) starting integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) vs. protease inhibitor (PI) or non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based ART. Since many PWH have switched from non-INSTI to INSTI-based regimens, we assessed weight over time among PWH switched to an INSTI regimen…

RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON InSTI

Weight gain and psychiatric symptoms (PSs) have been reported in persons living with HIV (PLWH) receiving ART, especially integrase strand transfer inhibitors (INSTI). Obesity and PSs are correlated with chronic inflammatory states characterized by insulin resistance. Resistin is a pro-inflammatory adipokine and plays a key role in the insulin responsiveness of peripheral tissues and the…

DEPRESSION COGNITIVE BEHAVIORAL THERAPY TO IMPROVE HIV-CVD RISK: A PILOT RCT

Depression is associated with an increased risk of cardiovascular disease in the HIV+ population. We hypothesized that reducing depressive symptoms would improve cardiovascular risk in HIV. We conducted a single-center, randomized (1:1), controlled, parallel-group, assessor-blinded trial comparing Beating the Blues (BtB) – an evidence-based, 8-session, internet cognitive behavioral therapy for depression – with usual care…

HIV AND AGEING: PRIMARY AND SECONDARY PREVENTION OF CAD AMONG PLHIV

With the introduction of combined antiretroviral therapy for HIV patients, the clinical focus has shifted from AIDS-related opportunistic infections to age-related co-morbidities, specifically cardiovascular disease (CVD). As of 2019, there are approximately 7,760 People living with HIV (PLHIV) in Sweden. This study aims to assess the incidence of MI and stroke among PLHIV in Sweden, as…

ASSOCIATION BETWEEN HIV AND THE PREVALENCE OF ATRIAL FIBRILLATION AND ATRIAL FLUTTER

People living with HIV are at increased risk for cardiovascular disease (CVD). The association between HIV serostatus and atrial arrhythmias is incompletely understood. This study was conducted to study the relationship between HIV and atrial fibrillation/flutter (AF/AFL). HIV infected (HIV+) and uninfected (HIV-) participants in the 4-city Multicenter AIDS Cohort (MACS) were assessed for AF/AFL…

MitoQ ATTENUATES EX VIVO PROATHEROGENIC EFFECTS OF HIV PLASMA IN CHRONIC TREATED HIV

The mechanisms that drive atherosclerotic cardiovascular disease (CVD) in treated HIV remain unclear. (Pre)clinical studies have shown that the antioxidant MitoQ improves vascular endothelial function by reducing reactive oxygen species production by mitochondria, but its effects in HIV-CVD are unknown.  We used an established model of arterial wall to assess ex vivo the impact of MitoQ…